A historical perspective on clonidine as an alpha-2A receptor agonist in the treatment of addictive behaviors: Focus on opioid dependence
Open accessAbstract
Clonidine operates through agonism at the alpha-2A receptor, a specific subtype of the alpha-2-adrenergic receptor located predominantly in the prefrontal cortex. By inhibiting the release of norepinephrine, which is responsible for withdrawal symptoms, clonidine effectively addresses withdrawal-related conditions such as anxiety, hypertension, and tachycardia. The groundbreaking work by Gold et al. demonstrated clonidine’s ability to counteract the effects of locus coeruleus stimulation, reshaping the understanding of opioid withdrawal within the field. In the 1980s, the efficacy of clonidine in facilitating the transition to long-acting injectable naltrexone was confirmed for individuals motivated to overcome opioid use disorders (OUDs), including physicians and executives. Despite challenges with compliance, naltrexone offers sustained blockade of opioid receptors, reducing the risk of overdose, intoxication, and relapse in motivated patients in recovery. The development of clonidine and naltrexone as treatment modalities for OUDs, and potentially other addictions, including behavioral ones, underscores the potential for translating neurobiological advancements from preclinical models (bench) to clinical practice (bedside), ushering in innovative approaches to addiction treatment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These genetic insights point to new therapeutic targets for pain management and addiction prevention and recovery.
“These genetic insights point to new therapeutic targets for pain management and addiction prevention and recovery.26,28–32”
From Beyond Stigma–Integrating Neurobiology, Genetics, and Awareness Integration Theory in Addiction Recovery (2026) · cites this paper as [30]
The References section (page unavailable) lists work on genetic addiction risk, but a reference title alone does not establish the claimed link between genetic insights and new therapeutic targets. Searches for genetic testing, pain management, and personalized addiction treatment found no passage in the paper making that link across pain management and addiction prevention or recovery. (LLM, conf=0.71)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 166 · Cited by 9
Research works printed but not linked: 6
- [3]Yasaei R, Saadabadi A. Clonidine. Treasure Island, FL: StatPearls Publishing; 2023. 29083638
- [10]Foye WO. Foye’s Principles of Medicinal Chemistry. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
- [14]Giannini AJ, Extein I, Gold MS, Pottash AL, Castellani S. Clonidine in mania. Drug Dev Res. 1983; 3(1): 101– 103.
- [38]Gold MS, Roehrich H. Treatment of opioid withdrawal with clonidine. ISI Atlas of Science. Pharmacology. 1987; 1741: 29– 32.
- [39]Gold MS, De R. Pharmacological activation and inhibition of noradrenergic activity after specific behaviors in nonhuman primates. Soc Neurosci. 1977; 3(783): 250.
- [132]Nestler EJ. Reinforcement and addictive disorders. In: Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. United States: McGraw Hill; 2009.
- Authors
- Gold, M. S., Blum, K., Bowirrat, A., Pinhasov, A., Bagchi, D., A. Dennen, C., K. Thanos, P., Hanna, C., Lewandrowski, K.-U., Sharafshah, A., Elman, I., & D. Badgaiyan, R.
- Affiliations
- Washington University in St. Louis (US)
- Eötvös Loránd University (HU)
- Ariel University (IL)
- Texas Southern University (US)
- University at Buffalo, State University of New York (US)
- Hospital Universitário Gaffrée e Guinle (BR)
- Guilan University of Medical Sciences (IR)
- Harvard University (US)
- Corresponding author
- Blum, Kenneth
- ORCID
- Venue
- INNOSC Theranostics and Pharmacological Sciences
- Publisher
- AccScience Publishing
- Published
- 2024-07-29
- Volume
- 7
- Issue
- 3
- Pages
- 1918
- ISSN
- 2705-0734 (ISSN-L)
- 2705-0823
- PMC
- PMC11308626
- OpenAlex
- W4401199623
- Cited by
- 9
- References
- 166
- Citations by year
- 2026: 5 · 2025: 4
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- INNOSC Theranostics and Pharmacological Sciences (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- National Institute of Neurological Disorders and Stroke (R01NS073884)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- clonidine, alpha2A-adrenergic receptor, opioid use disorder, naltrexone, opioid withdrawal, noradrenaline release, locus coeruleus, prefrontal cortex, addiction treatment, relapse prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
